Collegium Pharmaceutical competitors

Collegium Pharmaceutical's competitors include Depomed, Otonomy, Biogen and MyoKardia
Add company...
Collegium Pharmaceutical
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Depomed
Depomed is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Founding Date
Founding Date
2002
Founding Date
1995
Founding Date
2008
Founding Date
1978
Founding Date
2012
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Canton, US HQ
Locations
Newark, US HQ
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Locations
South San Francisco, US HQ
Employees
Employees
234
Employees
490
Employees
139
Employees
7,3001% decrease
Employees
1024% increase
Valuation ($)
Valuation ($)
603.7 m
Valuation ($)
551.9 m
Valuation ($)
100.9 m
Valuation ($)
69.3 b
Valuation ($)
2 b
Facebook likes
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
1.1 k
Facebook likes
3.1 k
Facebook likes
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
267
Twitter followers
19.4 k
Twitter followers
387

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$380.7m (FY, 2017)
Revenue (est.)
$1.2m (FY, 2017)
Revenue (est.)
$11.4b (FY, 2016)
Revenue (est.)
$22.5m (FY, 2017)
Cost of goods
Cost of goods
N/A
Cost of goods
$72.6m (FY, 2017)
Cost of goods
$3.1m (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$308.1m (FY, 2017)
Gross profit
($1.9m) (FY, 2017)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($74.9m) (FY, 2017)
Net income
($102.5m) (FY, 2017)
Net income
($90.1m) (FY, 2017)
Net income
$3.7b (FY, 2016)
Net income
($46m) (FY, 2017)

Operating

Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
4 (FY, 2016)
Phase I Trials Products
2 (FY, 2017)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
10 (FY, 2016)
Phase II Trials Products
1 (FY, 2017)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Preclinical Phase Products
Preclinical Phase Products
N/A
Preclinical Phase Products
N/A
Preclinical Phase Products
1 (FY, 2016)
Preclinical Phase Products
N/A
Preclinical Phase Products
3 (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 106m
Total funding raised
$ 875m
Total funding raised
$ 153.4m
Total funding raised
N/A
Total funding raised
$ 98m
For sources of this data, please see the company profileDownload Excel

View company profiles

Depomed
HQ
Newark, US
Employees
490

Depomed is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.

View company
Otonomy
HQ
San Diego, US
Employees
139

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
Biogen
HQ
Cambridge, US
Employees
7,300↓ 1% decrease

Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company